In the trading-volume change rankings for the 9 a.m. hour, SymBio Pharmaceuticals entered the rankings and extended its gains sharply. The stock hit its daily price limit yesterday after the company said it had agreed with UK regulators to proceed with an application for approval of BCV for the relevant indication, and buying interest continued today. HENNGE also entered the rankings, with trading volume rising sharply.
SymBio Pharmaceuticals entered the trading-volume change rankings for the 9 a.m. hour. The company announced yesterday that it had agreed with the UK's Medicines and Healthcare products Regulatory Agency to proceed with an application for marketing authorization for brincidofovir for the indication of adenovirus infection following hematopoietic stem-cell transplantation, sending the stock to its daily price limit yesterday.
HENNGE also appeared in the rankings on the same day, with trading volume expanding. The table lists HENNGE's trading volume and share-price change immediately below those of SymBio Pharmaceuticals. Specifically, HENNGE's trading volume was 1,563,700, its trading-volume change was 28.89% and its share-price change was 0.1976%. These were shown among the stocks ranking highly on a measure comparing them with the most recent 5-day average.
The rankings are based on changes in trading volume, and stocks with 20-day average trading value of ¥50 million or less are excluded. Other stocks mentioned in the article include NFJPX400, iFTPX Year 1 and DNC.